Unicycive Therapeutics (UNCY) EBT Margin (2022 - 2023)
Unicycive Therapeutics posted quarterly EBT Margin of 622.22% for Q1 2023, down 6.48% on a QoQ basis from 584.33% in Q3 2022.
Unicycive Therapeutics (UNCY) has 2 years of EBT Margin data on file, last reported at 622.22% in Q1 2023.
- For the quarter ending Q1 2023, EBT Margin changed N/A year-over-year to 622.22%; the trailing twelve-month figure through Dec 2023 stood at 2998.67% (changed N/A YoY), and the FY2023 full-year result was 2998.67%, down 109982.0% from the prior year.
- EBT Margin for Q1 2023 stood at 622.22%, down from 584.33% in the prior quarter.
- Across five years, EBT Margin topped out at 584.33% in Q3 2022 and bottomed at 622.22% in Q1 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -6.40% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 41.95% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 23.05% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 18.99% |
| 10 | Unicycive Therapeutics | 181.94 Mn | 127.36 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | -622.22% |
| Sep 30, 2022 | -584.33% |